COR · Q2 2026 Earnings

Customer optimization hangover → U.S. specialty acceleration → MSO platform deepening → Portfolio pruning and capacity commitment → MSO as the operating identity → Defensive recalibration on the top line.

The biggest tone shift is from confident upgrading to defensive recalibration in a single quarter. One quarter ago management raised the FY26 revenue guide from 5–7% to 7–9% and the U.S. OI growth guide by 500bps; this quarter the revenue guide was cut back to 4–6%, eating the entire prior raise and then some. The anchor quote: "Despite noise today, given some transitory items causing our results to be below expectations, we remain on track to deliver strong guidance for fiscal 2026." The pivot from "raising and reaffirming" to "noise today" and "transitory items" in 90 days is a posture shift that matters — management is no longer surfing tailwinds, they're managing through stacked headwinds.

GLP-1 framing has migrated from quantified tailwind to quantified disappointment across three quarters. In Q3 FY25 GLP-1s were a $1.4B +19% YoY contributor and management explicitly preempted the deceleration narrative. By Q4 FY25 they were a known FY26 comp pressure. This quarter the deceleration is fully crystallized: "a 5% delta in growth year over year represents approximately $2 billion in annual revenue." The shift signals GLP-1 is no longer a strategic talking point — it's now a $2B revenue gap management has to fill with other growth.

Brand-to-biosimilar conversion at the mail-order customer is the new structural surprise. This was not flagged in Q4 FY25 or Q1 FY26 prepared remarks. This quarter: "The third factor, which was not fully contemplated, was the speed of brand conversions for our large mail-order pharmacy customer." That management is admitting a forecasting miss on a known dynamic is unusual transparency — but also exposes that the FY26 model was built on biosimilar conversion timing assumptions that have now proven wrong, raising questions about FY27 visibility.

The MSO platform thesis is doing more heavy lifting in the narrative than ever before. Two quarters ago MSOs were a "natural extension"; this quarter they are the explicit reason gross margin expanded 45bps despite revenue softness: "the MSOs really bring up our gross margin and they bring up our operating margin also...the biggest reason for that was the MSO business." Mix shift to MSOs is now the proximate explanation for why a 300bps revenue cut produced a 50bps OI growth raise — but this also means MSO contribution must keep accelerating to offset structural pricing pressure in distribution.

Confidence on margin defense is being asserted rather than demonstrated. "we're very confident that we can maintain that dollar profit through these discussions...because of the scope and scale and quality of the services that we provide." Two quarters ago management was claiming credit for thesis execution; this quarter they are defending dollar-profit sustainability against WAC, IRA, and biosimilar pressure. The shift from offense to defense on margin language is subtle but meaningful for how to read the 14–16% U.S. OI growth reaffirmation.